Oral etretinate (Tegison) reduced the lesion size in 82-86% of patients in the first study,106 both when etretinate was the primary drug (19/22, followed by placebo) or when etretinate was used after crossover from placebo (18/22). Placebo reduced lesion size in only 4-3% (1/23) of patients who used placebo before etretinate. Use of placebo following etretinate resulted in no change in lesions for 95% of subjects (18/19).
In the second study,107 etretinate improved the overall grading of lesions in 89-100% of patients (8/9 subjects using etretinate before placebo and 6/6 subjects using etretinate after placebo use). Placebo improved lesion gradings in 17% of subjects who used placebo before crossing over to etretinate (1/6). For those subjects who crossed over to placebo from etretinate, only 11% had any further improvement (1/9).
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.